Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181018 | 0.85 | ALDH1A1 (0.67) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL1454189 | 0.83 | ALDH1A1 (0.67) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL27664706 | 0.82 | MAPT (0.76) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL4287857 | 0.80 | ALDH1A1 (0.66) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL3199881 | 0.80 | RAB9A (0.66) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL3191246 | 0.79 | NPC1 (1.00) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL22348661 | 0.78 | NPC1 (0.72) | NPC1MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL4292567 | 0.78 | RAB9A (0.59) | NPC1MAPTLMNAKMT2ARAB9A | |
| SCHEMBL25394468 | 0.76 | MEN1 (0.58) | NPC1MAPTLMNAALDH1A1KMT2A | |
| SCHEMBL9963854 | 0.76 | RAB9A (0.89) | NPC1MAPTLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674912-B2 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2010-03-09 | — | — | US | disclosed |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| CN-101175737-A | Pro-drugs of N-thiazol-2yl-benzamide derivatives | LUNDBECK & CO AS H (DK) | 2008-05-07 | — | — | CN | disclosed |
| EP-1877391-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. Lundbeck A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| CN-1870996-A | N-thiazol-2-yl-benzamide derivatives | LUNDBECK & CO AS H (DK) | 2006-11-29 | — | — | CN | disclosed |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
| WO-2006114093-A1 | PRO-DRUGS OF N-THIAZOL-2YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-11-02 | — | — | WO | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | NPC1 1022/4885MAPT 1300/4885LMNA 2722/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | NPC1 1022/4885MAPT 1300/4885LMNA 2722/4885 |
| US-20060264485-A1 | Pro-drugs of N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA2B, ADORA1 | NPC1 652/4885MAPT 1039/4885LMNA 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.